



ANTIVIRAUX ACTIFS SUR LES VIRUS RESPIRATOIRES

Enseignant : F. Van Bambeke

FARM2129 – année 2007-2008

03/04/2008

influenza

1

Médicaments des infections virales respiratoires

Adenovirus	-
Picornavirus	-
Entero	-
Rhino	-
Orthomyxovirus	
Influenza	inhibiteurs de neuraminidase : zanamivir, oseltamivir adamantananes (influenza A)
Paramyxovirus	
Parainfluenza	-
Respiratory syncytial virus	ribavirine
SARS virus	-

03/04/2008

influenza

2


ANTIVIRAUX ACTIFS SUR LE VIRUS INFLUENZA

03/04/2008

influenza


3

Le Virus de l'influenza: constituants



Electron micrographs of purified influenza virions. Hemagglutinin (HA) and neuraminidase (NA) can be seen on the envelope of viral particles. Ribonucleoproteins (RNPs) are located inside the virions.

Diagram of the influenza virus




03/04/2008

influenza


4

Virus Influenza: Antigènes de surface

Distribution of Influenza A Hemagglutinin Subtypes in Nature



Distribution of Influenza A Neuraminidases in Nature




http://www.brown.edu/Courses/Bio_160/Projects1999/flu/mechanism.html

03/04/2008

influenza

5


Influenza A Virus Shift



03/04/2008

influenza

6



Commissariat
interministériel Influenza

La Grippe

A distinguer :



Grippe saisonnière
(Maladie humaine)

→ Attendue chaque hiver



Cas humains de
grippe aviaire
(Zoonose)

→ Situation récente en Asie



Pandémie de grippe
(Zoonose évoluant en
maladie humaine)

→ Pourrait émerger un jour

03/04/2008

influenza


7

Histoire des pandémies ...

1889-90	A/H2N8	
1900-03	A/H3N8	
1918-19	A/H1N1	<i>Spanish Flu</i>
1957-58	A/H2N2	<i>Asian Flu</i>
1968-69	A/H3N2	<i>Hong Kong Flu</i>
(1977-78)	A/H1N1	<i>Russian Flu</i>



Australian Red Cross 1918



Life expectancy from 1900 to 2001 showing the impact of the 1918 influenza pandemic. Data are adapted from the National Vital Statistics Reports, Vol. 52, No. 14, February 18, 2004. (http://www.cdc.gov/nchs/data/dvs/nvsr52_14t12.pdf).



03/04/2008

influenza

8


Evolution des "maladies grippales" et de l'isolement d'*Influenza A*

Laboratoires Vigies

Influenza A

➤ l'évolution du nombre d'*Influenza A* est comparable à celle du nombre d'IRA grippales enregistrées par le réseau de médecins généralistes participant au programme de surveillance des IRA et de la grippe (figure 7).

Figure 7 : *Influenza A* : comparaison entre l'évolution par semaine du nombre d'*Influenza A* et celle des IRA grippales (2004-2005)




http://www.iph.fgov.be/epidemo/epifr/plabfr/plabanfr/05_082f_v.pdf

03/04/2008

influenza

9

Epidémiologie annuelle des infections par *Influenza*



<http://www.iph.fgov.be/flu/FR/22FR.htm>


03/04/2008

influenza

10

Voies de transmission

1. aérosolisation



2. Voie aérienne



3. Objets contaminés




03/04/2008

influenza

11

La grippe: signes cliniques




03/04/2008

influenza

12

Cibles des antiviraux



P. Palese Nature Medicine 10 : 2004

03/04/2008

influenza



13

ADAMANTANES

03/04/2008

influenza

14



INHIBITEURS DE NEURAMINIDASE


03/04/2008

influenza

17

La neuraminidase

Moscona, NEJM (2005) 353:1363-1373




03/04/2008

influenza

18

La neuraminidase



La neuraminidase clive l'acide sialique des glycoprotéines de surface cellulaire auxquelles sont attachées les nouvelles particules virales

Functions:

- favorise la libération des particules virales
- détruit les récepteurs de surface reconnus par les hémagglutinines
- prévient l'aggrégation des virus à la surface cellulaire
- prévient l'inactivation par le mucus respiratoire


03/04/2008

influenza

19

L'acide sialique

Lien osidique avec galactose (2 → 3)




03/04/2008

influenza

20

Découverte du premier inhibiteur ... 1969 !



2,4-dideoxy-2,3-didehydro-4-amino-D-N-acetylneuraminic acid

Meindl et al., Hoppe-Seyler's Z. Physiol. Chem., 350:1088-1092, 1969

03/04/2008

influenza

21

De 1969 à 1993...

Neuraminidase bound by sialic acid (yellow)
Catalytic residues are green, residues involved in binding are blue.



1983: structure of neuraminidase

- conservation des résidus du site actif
- variation des sites antigéniques

→ place pour du drug design !


Colman et al., Nature (1983) 303: 41-44

03/04/2008

influenza

22

Site actif de la neuraminidase




Von Itzstein., *Nature Drug Discovery* (2007) 6: 967

03/04/2008

influenza

23

De l'acide sialique au zanamivir... (1)




acide sialique ou N-acétyl-neuraminique
interaction COOH avec Arg 371

03/04/2008

influenza

24

De l'acide sialique au zanamivir... (2)



4-deoxy-4-amino ...

4-deoxy-4-guanidino...


interaction avec 1 puis 2 résidus conservés

03/04/2008

influenza

25

Le zanamivir





von Itzstein et al., Nature (1993) 363: 418-423, 1993

03/04/2008

influenza

26



Résistance: mutation de la cible

Neuraminidase

119 Glu → Gly:

- Résistance au zanamivir
(Glu 119 interagit avec guanidinium)

292 Arg → Lys (R292K):

- Résistance à l'oseltamivir
(Arg 292 interagit avec acide carboxylique mais conformation de la poche enzymatique adhoc pour le zanamivir)

274 His → Tyr (H274Y) et 294 Asn → Ser (N294S)

- Résistance à l'oseltamivir


Hemagglutinine

Certaines mutations (198 Thr → Ile) diminuent l'affinité pour le récepteur

03/04/2008

influenza

29



Moscona, A. *N Engl J Med* (2005)353:2633-2636

Mechanism of Resistance to Oseltamivir.

The neuraminidase active site changes shape to create a pocket for oseltamivir, whereas it accommodates zanamivir without such a change (Panel A). Any of several mutations may prevent the binding of oseltamivir by preventing the formation of this pocket (Panel B); the oseltamivir-resistant virus can nonetheless bind to the host-cell sialic acid receptor and to zanamivir. The pocket for oseltamivir, illustrated by key amino acids in Panel C, is created by the rotation of E276 and bonding of the amino acid to R224 — events that are prevented by the mutations R292K, N294S, and H274Y and therefore result in resistance to oseltamivir. An E119V mutation may permit the binding of a water molecule in the space created by the smaller valine, also interfering with oseltamivir binding. None of these mutations prevent the binding of zanamivir or of the natural sialic acid substrate.

03/04/2008

influenza

30

Comparaison des inhibiteurs de neuraminidase


propriété	zanamivir	oseltamivir
spectre	Influenza A et B	
Voie d'administration	Inhalation 10 mg 2X/jour	Voie orale: 75-150 mg 2 X/jour
Traitement (5 jours)	↘ durée des symptômes – grippe saisonnière	
Prophylaxie	4 semaines: ↘ du nb de personnes malades	6 semaines: ↘ du nb de personnes malades
Activité sur H5N1	Peu efficace chez les patients contaminés	
tolérance	Bonne sauf path. respir.	bonne

03/04/2008

influenza

31

Zanamivir: voie d'administration




<http://www.relenza.com/how-to-use-diskhaler.jsp?languages=French>

03/04/2008

influenza

32

Zanamivir: comment l'administrer correctement ?





<http://www.relenza.com/how-to-use-diskhaler.jsp?languages=French>

03/04/2008

influenza

33

Zanamivir: comment l'administrer correctement ?



1 dose: = 2 cupules


<http://www.relenza.com/how-to-use-diskhaler.jsp?languages=French>

03/04/2008

influenza

34

Zanamivir: efficacité clinique



On gagne 1-2 jours ...

Group	No of patients	Median	No of patients	Median	Difference (95% CI)	p
Return to normal activities (days)						
Intention to treat	228	9.0	227	<7.0	2.0 (0 to 4.0)	<0.001
Influenza positive	160	9.0	161	<7.0	2.0 (0.25 to 4.0)	<0.001
Sleep disturbance (days of 13)						
Intention to treat	228	3	223	3.0	0 (-1.0 to 1.0)	0.088
Influenza positive	160	3.0	159	2.0	1.0 (0 to 1.5)	0.047
Number of paracetamol tablets (days 1-4)						
Intention to treat	228	12	224	14.0	-2 (-6 to 0)	0.291
Influenza positive	160	13	159	14.0	-1 (-5 to 2)	0.854
Number of cough mixture spoonfuls (days 1-14)						
Intention to treat	228	9	224	7.0	2 (-3 to 5)	0.738
Influenza positive	160	12	159	7.0	5 (-1 to 9)	0.045

Table 3: Sleep disturbance, return to normal activities, and use of relief medications

The Lancet (1998) 352: 1877-1881

03/04/2008

influenza

35

Zanamivir: efficacité en prophylaxie

Table 2. Efficacy of Zanamivir in Prevention of Influenza Infection and Disease*

Outcome	Frequencies in Study Groups, No. (%)		Odds Ratio (95% CI)	Estimated Risk Ratio (95% CI)	Efficacy, 1 - Risk Ratio (95% CI), %
	Placebo (n = 554)	Zanamivir (n = 553)			
Laboratory-confirmed clinical influenza	34 (6)	11 (2)	0.31 (0.14-0.64)†	0.33 (0.17-0.61)	67 (39-83)
Laboratory-confirmed influenza with fever	19 (3)	3 (<1)	0.15 (0.03-0.53)†	0.16 (0.06-0.45)	84 (55-94)
All febrile illnesses	58 (10)	33 (6)	0.54 (0.34-0.86)‡	0.57 (0.38-0.86)	43 (14-62)
Influenza infection with or without illness	77 (14)	53 (10)	0.66 (0.44-0.97)§	0.69 (0.50-0.96)	31 (4-50)

*CI indicates confidence interval.

†P ≤ .001.

‡P = .009.

§P = .03.

JAMA (1999) 282: 31-35


03/04/2008

influenza

36

Et l'oseltamivir ?

Figure 3. Effect of Oral Oseltamivir Treatment on Viral Titers in Nasal Lavages Following Experimental Influenza A/Texas/36/91(H1N1) Infection



Traitement :
On gagne 1-2 jours ...


JAMA (1999) 282:31-36

03/04/2008

influenza

Prophylaxie :
efficace

Figure 2. Effect of Oral Oseltamivir Prophylaxis on Illness Following Experimental Influenza A/Texas/36/91(H1N1) Inoculation



The total symptom score area under the curve value was lower in the combined oseltamivir groups (n=21) compared with placebo (n=12); $P=.02$. Fourteen symptoms related to influenza were included in the score.

37

Zanamivir: effets secondaires et contre-indications

Important Safety Information

RELENZA IS NOT RECOMMENDED FOR TREATMENT OR PROPHYLAXIS OF INFLUENZA IN INDIVIDUALS WITH UNDERLYING AIRWAY DISEASE (SUCH AS ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE).

- ♦ Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
- ♦ RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
- ♦ RELENZA has not been proven effective for treatment of influenza in individuals with underlying airways disease.
- ♦ If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
- ♦ Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups

03/04/2008

influenza

38

Bénéfice potentiel des inhibiteurs de neuraminidase

Thérapeutique:

- ↘ durée des symptômes de 1-2 jours
- ↘ risque de transmission du virus
- ↘ risque de complications (sinusite, bronchite)
- ↘ usage d'antibiotiques

Prophylaxie:

- Prévention saisonnière de l'infection


03/04/2008

influenza

39

Panique à bord: A quand la grippe aviaire ?

Pourquoi est-elle si redoutable ?



De Clercq, Nature Drug Discovery (2006) 5:1015-25

03/04/2008

influenza

40

Panique à bord: A quand la grippe aviaire ?

Stockpiling of Antivirals



Objectif :
30% de la population belge devrait
avoir accès au traitement dès 2008




03/04/2008

influenza

41

Panique à bord: A quand la grippe aviaire ?



Conseils aux voyageurs

- Vérifier la liste des pays concernés
- Éviter le contact avec la volaille
- Hygiène des mains en toutes circonstances
- Hygiène culinaire, dont la cuisson
- Pas d'antiviraux en préventif
- Consulter un médecin si fièvre
< 7 jours après le retour

03/04/2008

influenza

42

Pharmacothérapie de la grippe

- Traitement symptomatique
 - antipyrétiques
 - éviter aspirine chez les enfants (syndrome de Reye)
 - selon les symptômes: décongestionnants, antitussifs
- Traitement antiviral
 - intérêt assez limité en traitement ...
 - commencer < 36 heures après le début des symptômes
 - prophylaxie de l'environnement familial ?
- Suivre la survenue de complications (personnes à risque!)
- Vaccination !

03/04/2008

influenza

43

Recommandations de vaccination

- Personnes à risque de complication:
 - > 65 ans
 - personnes vivant en institutions
 - co-morbidités
- Personnes susceptibles de transmettre la maladie à des personnes à risque (personnel médical, ...)



03/04/2008

influenza



44


ANTIVIRAUX ACTIFS SUR RESPIRATORY SYNCYTIAL VIRUS (RSV)

03/04/2008

influenza


45

Infections respiratoires à RSV



Respiratory Illnesses Caused by Respiratory Syncytial Virus (RSV)

Syndrome	Percentage Caused by RSV
Bronchiolitis	43-90
Pneumonia	5-40
Tracheobronchitis	10-30
Croup	3-10
Asymptomatic	0.3




Difference in age distribution of inpatients and outpatients with respiratory syncytial virus infection in Rochester, NY. Of infants requiring hospitalization, 70% were younger than 6 months. In comparison, 25% of the children treated as outpatients were younger than 6 months and 38% were older than 2 years.

03/04/2008


influenza

46

la ribavirine, un analogue de la guanosine



RIBAVIRINE




(deoxy)GUANOSINE

03/04/2008

influenza

47

Mode d'action de la ribavirine



De Clercq, Nature Drug Discovery, 2006

03/04/2008

influenza

48

Indications et propriétés pharmacologiques

Aérosol : traitement des infections à RSV
mais peu utilisé ... affection bénigne

Voie générale: adjuvant dans le traitement de l'hépatite C

Effets secondaires:

- Détérioration de la fonction respiratoire
- Anémie hémolytique + hypoplasie médullaire
(Concentration dans les globules rouges)

03/04/2008

influenza

49

Traitement des infections à RSV

Traitement symptomatique

- antipyrétique
- apport de fluides
- oxygène si nécessaire
- bronchodilatateurs
- cortocôides



Traitement antiviral

(ribavirine)



03/04/2008

influenza

50